Medlab Clinical Gets Ethics Approval for Human Trials Using Nanotech

Medical News reported that Medlab Clinical (ASX:MDC) has received ethics approval for two human trials that will use its nanotechnology based NanoCelle™ delivery platform.
As quoted in the publication:

Medlab will apply its nanotechnology delivery system, known as NanoCelle™, to an existing statin compound, Atorvastatin (commercially known as Lipitor) for patients suffering high levels of cholesterol.
The second trial will involve applying Nanocelle™ to Type II Diabetes patients using nanotechnology with an existing Insulin compound.
Medlab’s delivery platform involves converting off patent pharmaceuticals into nanoparticle form, with a view to developing new patented pharmaceuticals.

Medlab CEO, Sean Hall, said:

[W]e are only altering the delivery mechanism, without changing the molecule, meaning the trials can bypass animal models and move directly to Phase 0, the first clinical trial done among people, with the trials expected to be shorter as a result. Through the NanoCelle platform delivery mechanism, a fraction of the normal dosage is administered, bypassing oral intake and gastrointestinal absorption, which could lead to considerable reduction in pain or other side effects usually associated with the drugs.

Click here for the full article.